Treatment decisions in multiple sclerosis — insights from real-world observational studies
María Trojano(University of Bari Aldo Moro), Helmut Butzkueven(Monash Alfred Psychiatry Research centre), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Mar Tintoré(Vall d'Hebron Hospital Universitari), Pietro Iaffaldano(University of Bari Aldo Moro), Jan Hillert, Tim Spelman(Peter Doherty Institute), Maria Pia Sormani(University of Genoa), Tomáš Kalinčík(The Royal Melbourne Hospital)
Cited by 191
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k